Terms: = Breast cancer AND PRCC, Q92733, TPRC, RCCP1, MGC4723, MGC17178, ENSG00000143294, 5546 AND Prognosis
4 results:
1. Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma.
Wang Y; Tian X; Zhu SX; Xu WH; Anwaier A; Su JQ; Gan HL; Qu YY; Zhao JY; Zhang HL; Ye DW
World J Surg Oncol; 2023 Mar; 21(1):98. PubMed ID: 36927438
[TBL] [Abstract] [Full Text] [Related]
2. The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
Pathol Res Pract; 2022 Mar; 231():153802. PubMed ID: 35180650
[TBL] [Abstract] [Full Text] [Related]
3. A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma.
Gao Z; Zhang D; Duan Y; Yan L; Fan Y; Fang Z; Liu Z
PLoS One; 2019; 14(3):e0211491. PubMed ID: 30822312
[TBL] [Abstract] [Full Text] [Related]
4. Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Kaufmann MR; Schraml P; Hermanns T; Wenger RH; Camenisch G
Exp Mol Pathol; 2013 Jun; 94(3):453-7. PubMed ID: 23531419
[TBL] [Abstract] [Full Text] [Related]
